Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Real World Data
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Ardea Biosciences
Evaluate
November 08, 2017
Selecta feels the pain of gout
April 27, 2016
Ironwood’s bargain might be a poisoned chalice
December 14, 2015
Horizon pays $500m for gout clout
August 13, 2014
Lesinurad data far from a crystal clear win for Astra
June 13, 2014
Upcoming events: Light for lesinurad and MLN9708 data
April 23, 2014
M&A buoys small caps but the action is elsewhere
February 07, 2013
M&A activity cools in 2012 as break-ups loom
January 22, 2013
Biotech still relying on friends for financing in 2012
August 28, 2012
Pascal Soriot answers AstraZeneca’s 911 call
July 26, 2012
Nasdaq biotech surge threatens to burn investors again
May 09, 2012
Negative adcom vote on Arcalyst puts gout approval in doubt
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics